|
Post by peppy on Nov 3, 2022 8:44:02 GMT -5
262.72+9.07 (+3.58%) As of 09:42AM EDT. Market open.
Day's Range 254.01 - 262.71 52 Week Range 158.38 - 262.71
continuing up as I cut and paste.
|
|
|
Post by neil36 on Nov 3, 2022 12:30:31 GMT -5
UTHR up 18% since its earnings call, adding over $1.8 billion in market cap.
Its story? Tyvaso DPI
|
|
|
Post by harryx1 on Nov 3, 2022 14:31:09 GMT -5
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 3, 2022 15:53:42 GMT -5
|
|
|
Post by jkendra on Nov 4, 2022 11:48:06 GMT -5
|
|
|
Post by castlerockchris on Nov 4, 2022 12:30:07 GMT -5
UTHR up 18% since its earnings call, adding over $1.8 billion in market cap.
Its story? Tyvaso DPI Let's hope MNKD sees the same bump from their earnings call, that would put us back above $4. I am hoping that all the buyers and analysts are being cautious with MNKD right now, choosing to wait the couple of days between the conference calls before making any moves.
|
|
|
Post by peppy on Nov 30, 2022 10:40:55 GMT -5
|
|
|
Post by lennymnkd on Nov 30, 2022 19:26:48 GMT -5
Is it safe to say they are not buying us anytime soon . Because the arbitrage would be in our favor … 🤔or am I over Complicating it as usual.
|
|
|
Post by wyattdog on Dec 6, 2022 10:44:01 GMT -5
Morgan Stanley Boosts Price Target on United Therapeutics to $330 From $322, Maintains Overweight Rating 7:55 AM ET, 12/06/2022 - MT Newswires 07:55 AM EST, 12/06/2022 (MT Newswires) -- United Therapeutics (UTHR) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $150 to $375
|
|
|
Post by jkendra on Dec 15, 2022 8:45:29 GMT -5
news.bloomberglaw.com/pharma-and-life-sciences/humana-suit-accuses-united-therapeutics-of-insurance-fraudHumana Suit Accuses United Therapeutics of Insurance Fraud
Dec. 14, 2022, 11:18 AM United Therapeutics Corp. is using a tax-exempt program to earn “obscene” profits—at the expense of Medicare—off drugs it sells to patients at highly reduced costs, a private health insurer alleges. UT partnered with a patient-assistance charity in a “cynical scheme that has become inherent to the pharmaceutical industry,” Humana Inc. says in a complaint filed in the US District Court for the District of Maryland Tuesday. In the scheme, drugmakers pay kickbacks to patients to induce them to use particular drugs, thereby eliminating cost-sharing obligations imposed by Medicare and insurers as an economic check on drug prices, the complaint says. ...
|
|
|
Post by cretin11 on Dec 15, 2022 14:46:22 GMT -5
Imagine that, an insurance company accusing another entity of engaging in a “cynical scheme” to boost profits. Takes one to know one I guess.
|
|
|
Post by nylefty on Dec 20, 2022 20:10:39 GMT -5
Insider Sell: United Therapeutics BY MT Newswires — 4:39 PM ET 12/20/2022 04:39 PM EST, 12/20/2022 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson and CEO, on December 16, 2022, sold 16,000 shares in United Therapeutics (UTHR) for $4,387,354. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 651,845 shares of the company, with 130 shares held directly and 651,715 controlled indirectly. SEC Filing: www.sec.gov/Archives/edgar/data/1082554/000141588922012852/xslF345X03/form4-12202022_041201.xml
|
|
|
Post by mytakeonit on Dec 20, 2022 20:15:01 GMT -5
Well people have to buy Xmas presents ... what's in your wallet?
But, that's mytakeonit
|
|
|
Post by Clement on Dec 21, 2022 7:41:57 GMT -5
Insider Sell: United Therapeutics BY MT Newswires — 4:39 PM ET 12/20/2022 04:39 PM EST, 12/20/2022 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson and CEO, on December 16, 2022, sold 16,000 shares in United Therapeutics (UTHR) for $4,387,354. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 651,845 shares of the company, with 130 shares held directly and 651,715 controlled indirectly. SEC Filing: www.sec.gov/Archives/edgar/data/1082554/000141588922012852/xslF345X03/form4-12202022_041201.xml In the Form 4 we see that Rothblatt recently (12/16/22 and 12/19/22) exercised 16,000 shares worth of options and then sold them. The exercisable date was 12/31/13 at exercise price of $113.08. The expiration date was 12/31/23. Code M means "Exercise or conversion of derivative security exempted pursuant to Rule 16b-3". Code M footnote 1 (from the Form 4): "1. This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person. This plan will continue until the earlier of: (a) exhaustion of a tranche of 1,000,000 stock options that expire December 31, 2023; or (b) July 31, 2023." After the transactions, Rothblatt has control of 651,845 shares of common stock. Rothblatt also has "Number of derivative Securities Beneficially Owned Following Reported Transaction(s)" of 1,496,000. So we can calculate that the value of shares recently sold is less than 1% of Rothblatt's total holdings in the company.
|
|
|
Post by Clement on Jan 5, 2023 8:48:57 GMT -5
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41st annual J.P. Morgan Healthcare Conference in San Francisco. The session will take place on Monday, January 9, 2023, from 1:30 p.m. to 2:10 p.m., Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at ir.unither.com/events-and-presentations.
|
|